Calcium
Evidence Fact Sheet
Calcium is an essential mineral and the principal structural component of bone (hydroxyapatite), also acting as an intracellular second messenger for muscle, nerve and clotting function. Research doses span ~500-1200 mg/day elemental calcium. FDA-authorized SSA health claim (osteoporosis); EFSA- and ANVISA-authorized function claims.
Also known as: Ca · Calcium carbonate · Calcium citrate · Calcium citrate malate · Calcium bisglycinate · Coral calcium · Cálcio (PT) · Calcio (ES)
Overview
Calcium is an essential dietary mineral whose best-characterized role is incorporation into the hydroxyapatite crystal lattice of bone via osteoblast-mediated mineralization; it also serves as a cytosolic second messenger for skeletal and cardiac muscle excitation-contraction coupling, presynaptic neurotransmitter release, and activation of the coagulation cascade. Supplements appear as calcium carbonate (requires gastric acid, taken with meals), calcium citrate (absorbed with or without food), and chelated forms such as calcium bisglycinate. Research and intake-reference doses typically range from ~500-600 mg per single dose up to 1000-1200 mg/day elemental calcium, with absorption best supported by adequate vitamin D. Regulatory status is well established: the FDA authorizes a Significant Scientific Agreement health claim linking calcium plus vitamin D to reduced osteoporosis risk (21 CFR 101.72), EFSA authorizes multiple Article 13(1) function claims, and ANVISA lists authorized functional claims for "cálcio." This page reports research findings in studied populations and is not medical advice.
Mechanism of Action
Hydroxyapatite Ca10(PO4)6(OH)2 crystal incorporation into bone matrix (osteoblast-mediated mineralization) · Cytosolic Ca2+ second messenger signaling via troponin C and calmodulin for skeletal/cardiac muscle excitation-contraction coupling · Voltage-gated Ca2+ channel-mediated synaptic vesicle exocytosis and neurotransmitter release at presynaptic terminals · Activation of coagulation factors (Factor IV) including prothrombin to thrombin conversion in the clotting cascade · Cofactor for digestive lipase and amylase enzyme function · Regulation of cell cycle checkpoint progression and differentiation via Ca2+/calmodulin-dependent kinases
Body systems: MUSCULOSKELETAL · Musculoskeletal · Neurological & Cognitive · Cardiovascular · METABOLISM
Evidence-Based Benefits
Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — Calcium is not characterized as a treatment for any disease.
Pre-Eclampsia & Pregnancy Hypertension Prevention
Meta-analysis supported- RR 0.45pre-eclampsia · 95% CI 0.31-0.65
- 13 trials · 15,730high-dose Ca trials · women
- RR 0.65high blood pressure · CI 0.53-0.81
In this Cochrane meta-analysis, high-dose calcium supplementation (at least 1 g/day) during pregnancy was associated with roughly half the risk of pre-eclampsia and a lower risk of high blood pressure versus placebo. The authors graded the pre-eclampsia evidence as low-quality with substantial heterogeneity (I-squared 70%). This is calcium's most consistently reported clinical signal and underlies WHO antenatal guidance in low-intake populations; reported as a research finding, not treatment advice.
Reported effect: Pre-eclampsia: average RR 0.45 (95% CI 0.31 to 0.65), 13 trials, 15,730 women; high blood pressure: RR 0.65 (95% CI 0.53 to 0.81), 12 trials, 15,470 women
“average RR 0.45, 95% CI 0.31 to 0.65; I² = 70%; low‐quality evidence (13 trials, 15,730 women) ... risk ratio (RR) 0.65, 95% confidence interval (CI) 0.53 to 0.81; I² = 74% (12 trials, 15,470 women)”
Source: PMID 30277579 · Hofmeyr 2018 · Cochrane Database Syst Rev
Bone Loss & Fracture Prevention
Meta-analysis supported- RR 0.88any fracture · 95% CI 0.83-0.95
- 29 RCTs · 63,897trials · participants
- 0.54% / 1.19%less bone loss · hip / spine
In adults aged 50 and older, calcium (alone or with vitamin D) was associated with a 12% reduction in risk of any fracture and a measurably slower rate of bone loss at the hip and spine. The authors reported a larger effect in trials with high adherence and with calcium doses of 1200 mg or more. This is the canonical positive bone finding underpinning the FDA osteoporosis health claim.
Reported effect: 12% risk reduction in any fracture (RR 0.88, 95% CI 0.83-0.95); reduced rate of bone loss of 0.54% at hip and 1.19% at spine; 29 RCTs, n=63,897
“Treatment was associated with a 12% risk reduction in any type of fracture (RR 0.88, 95% CI: 0.83, 0.95) ... Treatment was associated with a reduced rate of bone loss at the hip of 0.54% (95% CI: 0.35, 0.73) and at the spine 1.19% (95% CI: 0.76, 1.61) ... Twenty-nine RCTs (n=63,897) were included in the review.”
Source: PMID 17720017 · Tang 2007 · Lancet
Fracture Incidence in Community-Dwelling Older Adults
Null / no benefit Meta-analysis supported- 33 trials · 51,145randomized trials · participants
- RR 1.53hip fracture · 95% CI 0.97-2.42
- no significant associationtotal fractures
Honest negative. This larger JAMA meta-analysis restricted to community-dwelling older adults found no significant association between calcium, vitamin D, or combined supplementation and the incidence of hip, nonvertebral, vertebral, or total fractures. The hip-fracture point estimate for calcium alone even trended upward (RR 1.53) though the confidence interval crossed 1. This tempers the older Tang result and is central to the ongoing debate over routine supplementation in generally healthy seniors.
Reported effect: 33 randomized trials, 51,145 participants; calcium and hip fracture RR 1.53 (95% CI 0.97 to 2.42); no significant association with nonvertebral, vertebral, or total fractures
“33 randomized trials involving 51 145 participants ... RR, 1.53 [95% CI, 0.97 to 2.42] ... No significant associations were found between calcium, vitamin D, or combined calcium and vitamin D supplements and the incidence of nonvertebral, vertebral, or total fractures.”
Source: PMID 29279934 · Zhao 2017 · JAMA
Blood Pressure
Meta-analysis supported- -1.86 mm Hgsystolic · 95% CI -2.91 to -0.81
- -0.99 mm Hgdiastolic · CI -1.61 to -0.37
- 40 trials · 2492meta-analyzed trials · subjects
In this meta-analysis of randomized trials (mean dose 1200 mg/day), calcium supplementation produced a small but statistically significant reduction in systolic and diastolic blood pressure. The magnitude is modest and, on its own, well below what would be clinically meaningful as a sole treatment, but it is directionally consistent with calcium's role in vascular smooth-muscle and the pregnancy hypertension data.
Reported effect: Systolic BP reduced by -1.86 mm Hg (95% CI -2.91 to -0.81) and diastolic BP by -0.99 mm Hg (-1.61 to -0.37); 40 trials of 71 identified, 2492 subjects
“Seventy-one trials were identified, 40 of which met the criteria for meta-analysis (total of 2492 subjects). ... Calcium supplementation (mean daily dose: 1200 mg) reduced systolic BP by -1.86 mm Hg (95% confidence interval: -2.91 to -0.81) and diastolic BP by -0.99 mm Hg (-1.61 to -0.37).”
Source: PMID 16673011 · van Mierlo 2006 · J Hum Hypertens
Colorectal Adenoma Prevention
Meta-analysis supported- RR 0.89any adenoma · fixed · CI 0.82-0.96
- 4 RCTsplacebo-controlled trials
- RR 0.92advanced adenomas · NS
Pooling four placebo-controlled randomized trials, supplemental calcium was associated with a modest reduction in the recurrence of any colorectal adenoma (high quality of evidence). The protective signal did not reach statistical significance for advanced adenomas, so the benefit is best framed as modest and limited to overall adenoma recurrence in studied populations.
Reported effect: Any adenoma: fixed-effects RR 0.89 (95% CI 0.82-0.96), random-effects RR 0.87 (95% CI 0.77-0.98); advanced adenomas not significant (fixed RR 0.92, 95% CI 0.75-1.13); 4 RCTs
“fixed-effects, RR = 0.89, 95%CI: 0.82-0.96; random-effects, RR = 0.87, 95%CI: 0.77-0.98; high quality of evidence ... the association between calcium treatment and advanced adenomas did not reach statistical significance (fixed-effects, RR = 0.92, 95%CI: 0.75-1.13; random-effects, RR = 0.92, 95%CI: 0.71-1.18; moderate quality of evidence)”
Source: PMID 27182169 · Bonovas 2016 · World J Gastroenterol
Fall Prevention in Older Adults
Null / no benefit Meta-analysis supported- 35 RCTs · 58,937trials · participants
- RR 0.85vit D 800-1000 IU · CI 0.74-0.95
Honest negative for calcium specifically. This network meta-analysis found that 800-1000 IU/day vitamin D, with or without calcium, reduced falls, but explicitly concluded that vitamin D regimens were more effective than calcium alone at preventing falls. The headline risk reduction here is attributable to vitamin D rather than to calcium on its own.
Reported effect: 35 RCTs, 58,937 participants; vitamin D 800-1000 IU/day with or without calcium RR 0.85 (95% CI 0.74-0.95); 800-1000 IU/d of vitamin D with or without calcium more effective than calcium alone
“35 RCTs involving 58,937 participants ... RR = 0.85, 95%CI: 0.74-0.95 ... 800-1000 IU/d of vitamin D with or without calcium were more effective in preventing falls than calcium alone.”
Source: PMID 38698349 · Tan 2024 · BMC Geriatr
Dosage (research context · not a recommendation)
Adults 19-50 y: 1000 mg/day elemental calcium (IOM RDA). Women >=51 y and adults >=71 y: 1200 mg/day. Pregnancy/lactation 19-50 y: 1000 mg/day. Upper Limit (UL): 2500 mg/day adults 19-50 y; 2000 mg/day adults >=51 y. Supplemental doses typically 500-600 mg per single dose (absorption saturation above ~500 mg). Best absorbed with vitamin D adequacy (>=600 IU/day, 800 IU/day for >=71 y).
Regulatory Status · 4 Markets
- US · FDA
- FDA-authorized SSA (Significant Scientific Agreement) health claim under 21 CFR 101.72 "Health claims: calcium, vitamin D, and osteoporosis." Two regulatory tracks: (e) calcium-only model claim, (f) calcium + vitamin D + physical activity model claim added by 73 FR 56486 (Sept 29, 2008). Required disclosures and qualifying levels per 21 CFR 101.72(c). DSHEA structure/function claims (e.g., "supports bone health," "supports muscle function") permitted with FDA disclaimer under 21 USC 343(r)(6). GRAS as a nutrient (21 CFR 184.1191 calcium carbonate; 184.1193 calcium chloride; 184.1195 calcium citrate; etc.).
- EU · EFSA
- EFSA-evaluated and EU Commission-authorized under Regulation (EC) No 1924/2006 via Commission Regulation (EU) No 432/2012 Annex (List of permitted health claims). Eight authorized Article 13(1) function claims for calcium covering blood clotting, energy-yielding metabolism, muscle function, neurotransmission, function of digestive enzymes, cell division and specialisation, maintenance of normal bones, and maintenance of normal teeth. Use restricted to foods that are at least a "source of calcium" per the Annex to Regulation (EC) No 1924/2006 (>=15% NRV per 100 g/ml for solids, >=7.5% NRV per 100 ml for liquids).
- CN · China
- Approved in China as a nutrient-supplement raw material (calcium is an essential mineral listed in the 2023 SAMR Catalogue of Health-Food Raw Materials — Nutrient Supplements) and as a nutrient fortifier under GB 14880-2012. Nutrient-supplement filing supports 'calcium supplementation'; the registered health-food function 'increases bone mineral density' has extensive SAMR registrations as precedent.
- BR · ANVISA
- Permitted as nutrient ingredient in suplementos alimentares (dietary supplements) under ANVISA RDC 243/2018 (with composition limits per IN 28/2018 Anexos I, III, IV). Six authorized functional claims listed in IN 28/2018 Anexo V for "Cálcio," restricted to supplements meeting minimum quantity thresholds in Anexo III. Source/high-content nutrition claims permitted per IN 75/2020. Permitted in food enrichment per RDC 54/2012 and infant formula per RDC 43/2011 and RDC 44/2011.
Authorized Claims
FDA — “Adequate calcium throughout life, as part of a well-balanced diet, may reduce the risk of osteoporosis.” (21 CFR 101.72(e) - Health claims: calcium, vitamin D, and osteoporosis - calcium-only model)
FDA — “Adequate calcium and vitamin D throughout life, as part of a well-balanced diet, may reduce the risk of osteoporosis.” (21 CFR 101.72(f) - Health claims: calcium, vitamin D, and osteoporosis - calcium + vitamin D + physical activity model (added by 73 FR 56486, Sept 29, 2008))
FDA — “Adequate calcium and vitamin D as part of a healthful diet, along with physical activity, may reduce the risk of osteoporosis in later life.” (21 CFR 101.72(f) - calcium + vitamin D + physical activity extended model)
EFSA — “Calcium contributes to normal blood clotting” (Reg 432/2012)
EFSA — “Calcium contributes to normal energy-yielding metabolism” (Reg 432/2012)
EFSA — “Calcium contributes to normal muscle function” (Reg 432/2012)
EFSA — “Calcium contributes to normal neurotransmission” (Reg 432/2012)
EFSA — “Calcium contributes to the normal function of digestive enzymes” (Reg 432/2012)
EFSA — “Calcium has a role in the process of cell division and specialisation” (Reg 432/2012)
EFSA — “Calcium is needed for the maintenance of normal bones” (Reg 432/2012)
EFSA — “Calcium is needed for the maintenance of normal teeth” (Reg 432/2012)
ANVISA — “O cálcio auxilia na formação e manutenção de ossos e dentes.” (IN 28/2018 Anexo V alegação funcional)
ANVISA — “O cálcio auxilia na coagulação do sangue.” (IN 28/2018 Anexo V alegação funcional)
ANVISA — “O cálcio auxilia no funcionamento muscular.” (IN 28/2018 Anexo V alegação funcional)
ANVISA — “O cálcio auxilia no funcionamento neuromuscular.” (IN 28/2018 Anexo V alegação funcional)
ANVISA — “O cálcio auxilia no processo de divisão celular.” (IN 28/2018 Anexo V alegação funcional)
ANVISA — “O cálcio auxilia no metabolismo energético.” (IN 28/2018 Anexo V alegação funcional)
Safety
Generally recognized as safe within UL. High supplemental doses (>2000 mg/d total) associated with hypercalcemia, milk-alkali syndrome, and possible nephrolithiasis (kidney stones) particularly in predisposed individuals. Cardiovascular safety of high-dose supplements (without vitamin D) remains debated; meta-analyses (Bolland et al.) suggested possible MI signal, but conclusion contested by NOF/ASBMR. Calcium impairs absorption of iron, zinc, levothyroxine, tetracyclines, fluoroquinolones, and bisphosphonates - separate dosing by 2-4 hours. Contraindicated in hypercalcemia, hypercalciuria, severe renal impairment, and active sarcoidosis without medical supervision. Calcium carbonate requires gastric acid for absorption (take with meals); calcium citrate absorbed with or without food and preferred in achlorhydria or PPI users.
Related
Goals: joint-bone · longevity-stack · athletic-performance · reproductive-health
Lifestyles: menopause · athletic-performance · senior-60-plus
References
PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.
- PMID 30277579 · Hofmeyr 2018 · Cochrane Database Syst Rev — Pre-Eclampsia & Pregnancy Hypertension Prevention
- PMID 17720017 · Tang 2007 · Lancet — Bone Loss & Fracture Prevention
- PMID 29279934 · Zhao 2017 · JAMA — Fracture Incidence in Community-Dwelling Older Adults
- PMID 16673011 · van Mierlo 2006 · J Hum Hypertens — Blood Pressure
- PMID 27182169 · Bonovas 2016 · World J Gastroenterol — Colorectal Adenoma Prevention
- PMID 38698349 · Tan 2024 · BMC Geriatr — Fall Prevention in Older Adults
Frequently Asked Questions
1. Does calcium actually prevent fractures?
The evidence is mixed and depends on the population. A 2007 Lancet meta-analysis of 29 RCTs (n=63,897) in adults 50+ reported a 12% reduction in any fracture (RR 0.88) plus slower bone loss at the hip and spine. However, a larger 2017 JAMA meta-analysis restricted to community-dwelling older adults (33 trials, 51,145 participants) found no significant association between calcium, vitamin D, or combined supplements and fracture incidence. So the bone-strengthening signal is real in pooled older-adult trials but does not hold up as a routine fracture-prevention measure in generally healthy, community-living seniors.
2. What is calcium's strongest clinical evidence?
Its most consistent signal is in pregnancy. A Cochrane meta-analysis (Hofmeyr 2018, 13 trials, 15,730 women) found high-dose calcium (at least 1 g/day) was associated with an average RR of 0.45 for pre-eclampsia and RR 0.65 for high blood pressure versus placebo, though the authors graded the evidence as low-quality with high heterogeneity. This is reported as a research finding in studied populations, not as treatment guidance.
3. Does calcium lower blood pressure?
Only slightly. A meta-analysis of randomized trials (van Mierlo 2006, 40 trials, 2492 subjects, mean dose 1200 mg/day) found calcium reduced systolic blood pressure by -1.86 mm Hg and diastolic by -0.99 mm Hg. These reductions are statistically significant but small, and the authors note they do not justify calcium as a stand-alone treatment for elevated blood pressure.
4. Are there areas where calcium does not help?
Yes. Beyond the null 2017 JAMA fracture result, a 2024 network meta-analysis (Tan, 35 RCTs, 58,937 participants) concluded that 800-1000 IU/day vitamin D with or without calcium (RR 0.85) was more effective at preventing falls than calcium alone, meaning calcium by itself was not the driver. And for colorectal adenomas, the 2016 meta-analysis showing a modest benefit for any adenoma (RR 0.89) found no statistically significant effect on advanced adenomas (RR 0.92).
Last evidence review: 2026-06-04